PharmaCyte Biotech (PMCB) director Walker received 119,170 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Wayne Remell Walker (director at PharmaCyte Biotech Inc., PMCB) reported that they received 119,170 Stock Option (Right to Buy) on Mar 31, 2026.
- Reporting person
- Walker Wayne Remell
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Grant or award (A) | Stock Option (Right to Buy)On 119,170 Common Stock1 | +119,170 | - | - | 119,170 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 119,170 direct
Footnotes from the filing
- 1. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Walker report in this PMCB Form 4?
Wayne Remell Walker (director at PharmaCyte Biotech Inc., PMCB) reported that they received 119,170 Stock Option (Right to Buy) on Mar 31, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PMCB
Earlier insider filings at PMCB
- Apr 2, 2026SEC Form 4 filed by Weinstein Robert
- Apr 2, 2026SEC Form 4 filed by Schechter Jonathan
- Apr 2, 2026SEC Form 4 filed by Abecassis Michael M
- Jan 7, 2026CEO and President Silverman Joshua bought $80,476 worth of shares (100,000 units at $0.80), increasing direct ownership by 32% to 416,250 units (SEC Form 4)
- Jan 7, 2026Director Schechter Jonathan bought $48,232 worth of shares (60,000 units at $0.80), increasing direct ownership by 45% to 192,500 units (SEC Form 4)
Quantisnow market dataNASDAQ
PMCB
PharmaCyte Biotech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for PMCB
Full PMCB profile on Quantisnow Follow PMCB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time